Royal Bank Of Canada Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Neurocrine Biosciences (NASDAQ:NBIX) had its target price raised by research analysts at Royal Bank Of Canada from $176.00 to $180.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target suggests a potential upside of 24.29% from the company’s previous close.

Several other analysts have also recently weighed in on the stock. Canaccord Genuity Group raised their target price on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. Citigroup raised their target price on shares of Neurocrine Biosciences from $204.00 to $242.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $185.00 target price on shares of Neurocrine Biosciences in a report on Monday, April 6th. UBS Group reduced their target price on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Finally, Wolfe Research started coverage on shares of Neurocrine Biosciences in a report on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $182.50.

Neurocrine Biosciences Stock Performance

Shares of NBIX traded up $9.77 during mid-day trading on Wednesday, hitting $144.83. 969,251 shares of the company’s stock were exchanged, compared to its average volume of 1,146,756. The company has a market cap of $14.57 billion, a price-to-earnings ratio of 31.12, a P/E/G ratio of 0.67 and a beta of 0.34. Neurocrine Biosciences has a fifty-two week low of $115.66 and a fifty-two week high of $160.18. The stock’s 50-day moving average is $130.37 and its 200-day moving average is $137.72.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.36 by ($0.48). The business had revenue of $805.50 million for the quarter, compared to analyst estimates of $804.21 million. Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The firm’s revenue for the quarter was up 28.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.69 EPS. As a group, equities research analysts anticipate that Neurocrine Biosciences will post 6.57 EPS for the current year.

Institutional Trading of Neurocrine Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Gallacher Capital Management LLC acquired a new stake in Neurocrine Biosciences during the first quarter worth approximately $232,000. Aware Super Pty Ltd as trustee of Aware Super acquired a new stake in Neurocrine Biosciences during the first quarter worth approximately $18,020,000. State of Michigan Retirement System raised its holdings in Neurocrine Biosciences by 2.5% during the first quarter. State of Michigan Retirement System now owns 24,181 shares of the company’s stock worth $3,186,000 after purchasing an additional 600 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Neurocrine Biosciences by 5.2% during the first quarter. Principal Financial Group Inc. now owns 238,161 shares of the company’s stock worth $31,375,000 after purchasing an additional 11,784 shares in the last quarter. Finally, Chicago Partners Investment Group LLC raised its holdings in Neurocrine Biosciences by 37.9% during the first quarter. Chicago Partners Investment Group LLC now owns 7,389 shares of the company’s stock worth $969,000 after purchasing an additional 2,030 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Wedbush raised its price target on NBIX to $176 and kept an “outperform” rating, implying meaningful upside and likely supporting buy-side interest. Benzinga
• Positive Sentiment: Q1 results beat expectations: EPS and revenue topped consensus, net product sales rose ~44% YoY to roughly $811M, and management reaffirmed full-year INGREZZA sales guidance of $2.7–$2.8B — data that directly support valuation and near-term cash flow visibility. Q1 Press Release
• Positive Sentiment: INGREZZA sales were a key driver of the better-than-expected quarter, cited by multiple outlets — supporting the commercial growth story and analyst upgrades. Investing.com
• Positive Sentiment: Publication of expert recommendations for glucocorticoid dose reduction after initiating CRENESSITY (crinecerfont) — published in a peer-reviewed journal — should help clinicians reduce steroid burden in CAH patients and may accelerate real-world adoption. PR Newswire – CRENESSITY publication
• Positive Sentiment: Neurocrine announced a definitive agreement to acquire Soleno Therapeutics (including VYKAT XR for hyperphagia in Prader‑Willi), expanding the company’s pipeline and near-term commercial opportunities; expected close in Q2 2026. Acquisition announcement
• Neutral Sentiment: Pipeline progress: initiation of a Phase 2 study of NBI-1117570 (M1/M4 agonist) in schizophrenia — a positive clinical update but earlier-stage and longer horizon for value realization. Seeking Alpha – presentation
• Neutral Sentiment: Analyst/market coverage and events: company to present at the Bank of America Health Care Conference (May 12) and several earnings call transcripts/analyst notes are circulating — useful for deeper due diligence but not immediate catalysts. Conference notice

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.